Webinar: Cell-Based Screening - Accelerating Therapeutic Development

Therapeutics development benefits substantially from physiologically relevant assays, ideally ones using disease-relevant cells or organoids. Cell-based assays in small-molecule drug discovery have traditionally relied on stable cell lines to deliver consistent assay performance at screening scale. However, stable cell line development can be costly and time consuming. For protein or cell-based immunotherapeutic discovery, phage display is considered the gold standard, but its long selection cycles and complex downstream development can create bottlenecks.

In this DDN webinar, MaxCyte shares how our advanced transfection technology enables the development of faster, more flexible cell-based screening assays, illustrated by case studies and real user datasets.

Key topics covered

Benefits and challenges of cell-based assays
How transient transfection with MaxCyte optimizes assay development
Mammalian display screening for antibody and cell therapy discovery

Speaker

James Brady, PhD

Senior Vice President of Technical Applications & Customer Support at MaxCyte

Dr. Brady is an experienced biotechnology industry professional with expertise in gene and cellular therapy, biologics and drug discovery. Previously, he was a senior scientist at Genetic Therapy, a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments, and a group leader at MetaMorphix, managing the company’s transgenic and genetic research programs. Dr. Brady earned a Master of Business Administration in finance from Johns Hopkins University. He completed his postdoctoral fellowship at the National Eye Institute of the National Institutes of Health in Bethesda, Maryland, after obtaining a PhD in genetics from Indiana University in Bloomington, Indiana, and a Bachelor of Science in biology from the College of William and Mary in Virginia.